Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Gastrointestinal 1 Endocrine 1

Conditions

Differentiated Thyroid Cancer 1

Interventions

Cisplatin 144 Radiotherapy 71 Fluorouracil 50 Radiotherapy, Intensity-Modulated 45 Docetaxel 39 Gemcitabine 38 Cetuximab 38 Carboplatin 31 pembrolizumab 25 Capecitabine 22 Drug Therapy 17 toripalimab 14 Paclitaxel 14 camrelizumab 10 Surgical Procedures, Operative 10 Nivolumab 10 Chemoradiotherapy 10 nimotuzumab 9 Radiation 9 Neoadjuvant Therapy 8 Methotrexate 8 Magnetic Resonance Spectroscopy 8 Chemotherapy, Adjuvant 8 nedaplatin 7 Thyrotropin Alfa 7 Platinum 7 tislelizumab 6 spartalizumab 6 Standard of Care 6 Specimen Handling 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × donafenib × Head & Neck × Clear all

NCT03602495 2021-12-13

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Terminated

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡